Charles Schwab Investment Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,698,359 shares of the biopharmaceutical company’s stock after purchasing an additional 15,902 shares during the […]